{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epstein+Barr+Virus+Infections&page=3", "query": { "condition": "Epstein Barr Virus Infections", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 831, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epstein+Barr+Virus+Infections&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epstein+Barr+Virus+Infections&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T13:09:21.639Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00020111", "title": "Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 47, "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 38 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020111" }, { "nct_id": "NCT00589381", "title": "Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fenretinide lipid matrix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-08", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 4, "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • Bethesda, Maryland", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589381" }, { "nct_id": "NCT00004132", "title": "Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Oral Complications", "Radiation Toxicity" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004132" }, { "nct_id": "NCT01859819", "title": "Treatment for Advanced B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large Cell Lymphoma", "Burkitt's Lymphoma", "High Grade B-cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "IT Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "31 Years", "sex": "ALL", "summary": "3 Years to 31 Years" }, "enrollment_count": 45, "start_date": "2013-01", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 5, "location_summary": "Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Valhalla", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859819" }, { "nct_id": "NCT05544019", "title": "Study of SGR-1505 in Mature B-Cell Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mature B-Cell Neoplasm", "Non Hodgkin Lymphoma", "DLBCL", "Waldenstrom Macroglobulinemia", "MALT Lymphoma", "Follicular Lymphoma", "Pediatric-Type Follicular Lymphoma", "IRF4 Gene Rearrangement", "EBV-Positive DLBCL, Nos", "Burkitt Lymphoma", "Plasmablastic Lymphoma", "High-grade B-cell Lymphoma", "Primary Cutaneous Follicle Center Lymphoma", "Primary Effusion Lymphoma", "Mantle Cell Lymphoma", "DLBCL Germinal Center B-Cell Type", "Primary Mediastinal Large B Cell Lymphoma", "T-Cell/Histiocyte Rich Lymphoma", "ALK-Positive Large B-Cell Lymphoma", "Primary Cutaneous Diffuse Large B-Cell Lymphoma", "Splenic Marginal Zone Lymphoma", "Chronic Lymphocytic Leukemia", "Nodal Marginal Zone Lymphoma", "HHV8-Positive DLBCL, Nos", "Lymphoplasmacytic Lymphoma", "Duodenal-Type Follicular Lymphoma" ], "interventions": [ { "name": "SGR-1505", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Schrödinger, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-04-10", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Newark", "state": "Delaware" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544019" }, { "nct_id": "NCT00079222", "title": "Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "itraconazole", "type": "DRUG" }, { "name": "voriconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079222" }, { "nct_id": "NCT00002956", "title": "Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "1996-11", "completion_date": "2002-02", "has_results": false, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002956" }, { "nct_id": "NCT00016172", "title": "ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "picoplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-11", "completion_date": "2002-04", "has_results": false, "last_update_posted_date": "2013-06-18", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016172" }, { "nct_id": "NCT02879695", "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 28, "start_date": "2017-10-25", "completion_date": "2027-07-18", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879695" }, { "nct_id": "NCT00301912", "title": "Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 0, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-10-02", "last_synced_at": "2026-10-03T13:09:21.639Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301912" } ] }